Last verified · v1.0

Calculator · health

Left Ventricular Mass Index (Lvmi) Calculator

Compute LV mass (g) and LVMI from echo measurements (IVSd, LVIDd, PWTd) via the Devereux equation. Supports BSA and height^2.7 indexing for LVH detection.

FreeInstantNo signupOpen source

Inputs

Interventricular Septum Thickness (IVSd)

LV Internal Diameter at End-Diastole (LVIDd)

Posterior Wall Thickness (PWTd)

Height

Weight

Indexing Method

Left Ventricular Mass Index

—

Get a plain-English breakdown of your result with practical next steps.

Left Ventricular Mass Index—g/m²

The formula

How the
result is
computed.

What Is the Left Ventricular Mass Index (LVMI)?

The Left Ventricular Mass Index (LVMI) is a standardized cardiac measurement that quantifies the mass of the left ventricle relative to body size. Clinicians use LVMI to detect left ventricular hypertrophy (LVH), a structural cardiac adaptation strongly linked to hypertension, aortic stenosis, and elevated cardiovascular mortality. Indexing raw LV mass to body size corrects for the natural variation in heart dimensions across patients of different builds, enabling clinically meaningful comparisons against validated thresholds.

The ASE-Recommended Devereux Formula

This lv mass index calculator uses the corrected ASE (American Society of Echocardiography) method, known as the Devereux equation, to compute LV mass from three standard 2D echocardiographic linear dimensions:

LVM (g) = 0.8 × [1.04 × ((IVSd + LVIDd + PWTd)³ − LVIDd³)] + 0.6

The constant 1.04 represents the assumed specific gravity of myocardial tissue (1.04 g/mL). The cubic terms estimate the total ellipsoidal volume of the LV including walls, minus the internal chamber volume, yielding net myocardial tissue volume in milliliters. Multiplying by 1.04 converts volume (mL) to mass (g). The correction factor 0.8 and additive constant 0.6 were derived empirically to minimize systematic overestimation compared to autopsy-validated weights, as described by Devereux et al. — Corrected ASE Method for LV Mass (Columbia Academic Commons). Validation studies confirm correlation coefficients of approximately r = 0.90 between this formula and post-mortem LV mass measurements.

Input Variables Explained

IVSd — Interventricular Septum Thickness at end-diastole (cm): the septal wall separating the two ventricles, measured at maximal filling; normal range 0.6–1.0 cm in adults.
LVIDd — LV Internal Diameter at end-diastole (cm): internal chamber width at peak filling; normal adult range 3.9–5.3 cm.
PWTd — Posterior Wall Thickness at end-diastole (cm): thickness of the LV free wall opposite the septum; normal range 0.6–1.0 cm.
Height and Weight: used to compute body surface area via the Mosteller formula or to apply the allometric height exponent for size indexing.

Indexing LV Mass to Body Size

Raw LV mass cannot distinguish true pathological hypertrophy from the physiologically larger hearts found in taller or heavier individuals. Two validated indexing methods are provided:

Method 1: Body Surface Area (BSA) — ASE Recommended

BSA is calculated using the Mosteller formula: BSA (m²) = √(Height(cm) × Weight(kg) ÷ 3600). LVMI is then: LVMI (g/m²) = LVM ÷ BSA. According to echocardiography-based LV mass estimation research (PMC1183230), BSA indexing is the most widely validated normalization method in clinical practice. ASE/EACVI 2015 LVH cutoffs: >115 g/m² in men and >95 g/m² in women.

Method 2: Height^2.7 Indexing

LVMI = LVM ÷ [height(m)]^2.7, expressed in g/m^2.7. Research by Korcarz et al. (2016) demonstrates that this allometric exponent reduces obesity-related confounding present in BSA indexing, since adipose tissue inflates BSA without proportionally increasing cardiac workload. LVH cutoffs: >48 g/m^2.7 in men and >44 g/m^2.7 in women.

Worked Clinical Example

A 68 kg, 170 cm male presents for hypertension follow-up. Echocardiographic measurements: IVSd = 1.2 cm, LVIDd = 5.0 cm, PWTd = 1.1 cm.

Wall sum: 1.2 + 5.0 + 1.1 = 7.3 cm → 7.3³ = 389.0 cm³
Chamber volume: 5.0³ = 125.0 cm³
LVM = 0.8 × [1.04 × (389.0 − 125.0)] + 0.6 = 0.8 × 274.6 + 0.6 ≈ 220 g
BSA (Mosteller) = √(170 × 68 ÷ 3600) ≈ 1.79 m²
LVMI = 220 ÷ 1.79 ≈ 123 g/m² → exceeds male threshold of 115 g/m², confirming LVH

Clinical Significance and Monitoring

LVH is an independent predictor of myocardial infarction, stroke, heart failure, and sudden cardiac death, even after adjusting for blood pressure levels. Each 10 g/m² increment in BSA-indexed LVMI carries a measurable increase in cardiovascular event risk. Serial LVMI measurements guide antihypertensive therapy: effective blood pressure control typically reduces LVMI by 10–20 g/m² over 12–24 months. ACE inhibitors and ARBs show particularly favorable LVH regression profiles in randomized trials. Aortic valve replacement in severe aortic stenosis can reduce LVMI by 30–50 g/m² within one to two years. The lv mass index calculator automates the multi-step Devereux computation, reducing transcription error and saving time in busy echocardiography laboratories and outpatient cardiology clinics.

Reference

Frequently asked questions

What is a normal left ventricular mass index value?

Normal LVMI cutoffs per ASE/EACVI 2015 guidelines are 115 g/m2 or less for men and 95 g/m2 or less for women when indexed to body surface area. Using height^2.7 indexing, normal values are 48 g/m^2.7 or less for men and 44 g/m^2.7 or less for women. Values above these sex-specific thresholds indicate left ventricular hypertrophy (LVH), an independent risk factor for cardiovascular events including stroke, heart failure, and sudden cardiac death.

What causes elevated LVMI and left ventricular hypertrophy?

Elevated LVMI most commonly results from chronic pressure overload caused by systemic hypertension or aortic stenosis, forcing the LV to thicken its walls to maintain output against increased resistance. Volume overload from aortic or mitral regurgitation, chronic kidney disease, obesity, and endurance athletics are additional recognized causes. Distinguishing pathological from physiological hypertrophy is clinically important because management strategies differ substantially between these etiologies.

How accurate is the Devereux formula for computing LV mass?

The corrected ASE Devereux equation demonstrates strong correlation (r approximately 0.90) with autopsy-validated LV mass measurements when linear echocardiographic dimensions are accurately obtained from 2D-guided M-mode imaging. Accuracy depends heavily on image quality and operator technique. The formula may overestimate LV mass by 6 to 20 percent in patients with regional wall motion abnormalities or non-uniform wall thickness, which limits its reliability in ischemic cardiomyopathy and segmental hypertrophy.

Should BSA or height^2.7 be used to index LV mass?

BSA indexing using the Mosteller formula is the ASE-recommended standard and the most extensively published normalization method, making it the preferred choice for most clinical and research contexts. Height^2.7 indexing is advantageous in obese patients because excess adipose tissue inflates BSA without proportionally increasing cardiac workload, potentially masking true LVH. Korcarz et al. (2016) found height^2.7 indexing superior for detecting LVH in populations with high rates of obesity and obstructive sleep apnea.

Which echocardiographic measurements are required to calculate LVMI?

Three linear measurements obtained at end-diastole are required: interventricular septum thickness (IVSd), LV internal diameter (LVIDd), and posterior wall thickness (PWTd), all expressed in centimeters. These dimensions are obtained from the parasternal long-axis view using 2D-guided M-mode echocardiography per ASE/EACVI guidelines. Patient height in centimeters and body weight in kilograms are also needed to compute body surface area or apply the allometric height-based indexing exponent.

Can LVMI decrease with treatment, and how much regression is expected?

Yes, LVMI regresses meaningfully with appropriate treatment. Effective antihypertensive therapy — particularly with ACE inhibitors, ARBs, or calcium channel blockers — typically reduces BSA-indexed LVMI by 10 to 20 g/m2 over 12 to 24 months of optimized therapy. Aortic valve replacement for severe aortic stenosis can reduce LVMI by 30 to 50 g/m2 within one to two years post-surgery. Serial LVMI monitoring every 12 to 24 months is recommended to assess therapeutic response and guide ongoing medication adjustments.